曲美他嗪辅助环磷腺苷葡胺治疗VMC患者的效果观察  

Effects of trimetazidine supplemented with meglumine adenosine cyclophosphate in the treatment of patients with VMC

作　　者：乔燕燕[1] Qiao Yan-yan(Department of Cardiovascular Medicine,The First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,Henan,China)

机构地区：[1]河南科技大学第一附属医院心血管内科,河南洛阳471000

出　　处：《四川生理科学杂志》2024年第1期78-80,202,共4页Sichuan Journal of Physiological Sciences

摘　　要：目的:探讨曲美他嗪辅助环磷腺苷葡胺治疗病毒性心肌炎(Viralmyocarditis,VMC)患者对外周血T淋巴细胞、心肌酶谱的影响。方法:选取我院2020年10月至2021年12月收治的80例VMC患者为研究对象,随机分为对照组与观察组,各40例,对照组采用环磷腺苷葡胺治疗,观察组在对照组基础上联用曲美他嗪。治疗2 w后,对比两组临床疗效、心功能、血清T淋巴细胞亚群水平、心肌酶谱及不良反应发生情况。结果:观察组的临床有效率较对照组高(P<0.05);观察组的左心室射血分数、心脏指数均较对照组高(P<0.05);观察组的血清谷草转氨酶、肌酸激酶和肌酸激酶同工酶水平均较对照组低(P<0.05);观察组的CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)均较对照组高(P<0.05),CD8^(+)水平较对照组低(P<0.05);两组治疗期间不良反应发生率无统计学差异(P>0.05)。结论:曲美他嗪辅助环磷腺苷葡胺治疗VMC临床疗效显著,有助改善患者心肌酶谱,改善心功能,提高免疫功能。Objective:To explore the effects of trimetazidine supplemented with meglumine adenosine cyclophosphate on peripheral blood T lymphocytes and myocardial enzymes in treating patients with viral myocarditis(VMC).Methods:80 patients with VMC admitted to the hospital from October 2020 to December 2021 were selected as the research subjects and they were randomly divided into control group and observation group,with 40 cases in each group.The control group was treated with meglumine adenosine cyclophosphate while the observation group was combined with trimetazidine on the basis of the control group.After 2 weeks of treatment,the clinical efficacy,cardiac function,serum T lymphocyte subsets levels,myocardial enzymes and occurrence of adverse reactions were compared between the two groups.Results:After 2 weeks of treatment,the clinical effective rate in observation group was higher compared with that in control group(P<0.05).The left ventricular ejection fraction and cardiac index in observation group were higher than those in control group(P<0.05).The levels of serum aspartate aminotransferase,creatine kinase and creatine kinase isoenzyme were lower in observation group compared to control group(P<0.05).The CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in observation group were higher than those in control group(P<0.05)while the CD8^(+)was lower than that in control group(P<0.05).There were no statistical differences in the incidence rates of adverse reactions between the two groups during treatment(P>0.05).Conclusion:Trimetazidine supplemented with meglumine adenosine cyclophosphate has a significant clinical efficacy in the treatment of VMC,and it can help to reduce the myocardial enzymes,improve the cardiac function and enhance the immune function.

关 键 词：环磷腺苷葡胺 曲美他嗪 病毒性心肌炎 T淋巴细胞 心肌酶谱 

分 类 号：R542.21[医药卫生—心血管疾病]